A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

@article{Atzori2011API,
  title={A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.},
  author={Francesco Atzori and Josep Tabernero and Andr{\'e}s Cervantes and Ludmila Prudkin and Jordi S. Andreu and Edith Rodr{\'i}guez-Braun and Amparo Domingo and Jorge Guijarro and Cristina G{\'a}mez and Jordi Rod{\'o}n and Serena Di Cosimo and Holly D. H. Brown and Jason B. Clark and James S. Hardwick and Robert A. Beckman and William D. Hanley and Karl Hsu and Emiliano Calvo and Susana Rosell{\'o} and Ronald B. Langdon and Jos{\'e} Baselga},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 19},
  pages={6304-12}
}
PURPOSE Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to IGF-1R preventing receptor activation. This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose. EXPERIMENTAL DESIGN Patients with tumors… CONTINUE READING